Q Biomed (OTCMKTS:QBIO – Get Free Report) and Concentra Group Holdings Parent (NYSE:CON – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Valuation and Earnings
This table compares Q Biomed and Concentra Group Holdings Parent”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Q Biomed | N/A | N/A | N/A | ($0.02) | N/A |
| Concentra Group Holdings Parent | $2.16 billion | 1.78 | $166.41 million | $1.39 | 21.69 |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Q Biomed and Concentra Group Holdings Parent, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Q Biomed | 0 | 0 | 0 | 0 | 0.00 |
| Concentra Group Holdings Parent | 0 | 1 | 6 | 0 | 2.86 |
Concentra Group Holdings Parent has a consensus price target of $30.20, indicating a potential upside of 0.17%. Given Concentra Group Holdings Parent’s stronger consensus rating and higher possible upside, analysts plainly believe Concentra Group Holdings Parent is more favorable than Q Biomed.
Profitability
This table compares Q Biomed and Concentra Group Holdings Parent’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Q Biomed | N/A | N/A | N/A |
| Concentra Group Holdings Parent | 7.97% | 47.14% | 6.48% |
Summary
Concentra Group Holdings Parent beats Q Biomed on 8 of the 8 factors compared between the two stocks.
About Q Biomed
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
About Concentra Group Holdings Parent
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.
Receive News & Ratings for Q Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
